Difference between revisions of "The Regents of the University of California patent applications published on November 30th, 2023"

From WikiPatents
Jump to navigation Jump to search
 
(22 intermediate revisions by the same user not shown)
Line 28: Line 28:
 
==Patent applications for The Regents of the University of California on November 30th, 2023==
 
==Patent applications for The Regents of the University of California on November 30th, 2023==
  
−
===METHODS FOR NON-INVASIVE, LABEL-FREE IMAGING OF CELLULAR IMMUNE RESPONSE IN HUMAN SKIN USING A NONLINEAR OPTICAL MICROSCOPY IMAGING SYSTEM ([[US Patent Application 18202874. METHODS FOR NON-INVASIVE, LABEL-FREE IMAGING OF CELLULAR IMMUNE RESPONSE IN HUMAN SKIN USING A NONLINEAR OPTICAL MICROSCOPY IMAGING SYSTEM simplified abstract|18202874]])===
+
===METHODS FOR NON-INVASIVE, LABEL-FREE IMAGING OF CELLULAR IMMUNE RESPONSE IN HUMAN SKIN USING A NONLINEAR OPTICAL MICROSCOPY IMAGING SYSTEM ([[US Patent Application 18202874. METHODS FOR NON-INVASIVE, LABEL-FREE IMAGING OF CELLULAR IMMUNE RESPONSE IN HUMAN SKIN USING A NONLINEAR OPTICAL MICROSCOPY IMAGING SYSTEM simplified abstract (The Regents of the University of California)|18202874]])===
  
  
Line 36: Line 36:
  
  
−
'''Brief explanation'''
+
===COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS ([[US Patent Application 18028311. COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS simplified abstract (The Regents of the University of California)|18028311]])===
−
- The patent application describes noninvasive methods for identifying and characterizing immune cell populations in human skin.
 
−
- The methods use advanced imaging systems based on nonlinear optical microscopy.
 
−
- The images generated by the imaging systems are analyzed to detect, identify, differentiate, and quantify immune cell populations in human skin.
 
−
- The immune cell populations are identified based on their morphological, metabolic, and behavioral signatures.
 
−
 
 
−
'''Abstract'''
 
−
The disclosure provides noninvasive methods for the in vivo identification and characterization of various immune cell populations in human skin. The methods of the disclosure employ advanced imaging systems based on nonlinear optical microscopy to generate images that are analyzed to detect, identify, differentiate, and quantify immune cell populations in human skin by their morphological, metabolic and behavioral signatures.
 
−
 
 
−
===COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS ([[US Patent Application 18028311. COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS simplified abstract|18028311]])===
 
  
  
Line 53: Line 44:
  
  
−
'''Brief explanation'''
+
===CONJOINT THERAPIES FOR TREATING VIRAL INFECTIONS ([[US Patent Application 18178266. CONJOINT THERAPIES FOR TREATING VIRAL INFECTIONS simplified abstract (The Regents of the University of California)|18178266]])===
−
- The patent application proposes the use of GABA-receptor agonists, either alone or in combination with other compounds, to treat and prevent infections caused by bacteria, fungi, and viruses.
 
−
- The combination of GABA-receptor agonists with positive PAMs, anti-inflammatory compounds, and antiviral treatments is suggested to enhance the effectiveness of the treatment.
 
−
- The goal of the invention is to ameliorate infection-related medical conditions, including those caused by the coronavirus.
 
−
- The use of GABA-receptor agonists is expected to inhibit viral replication, particularly in the case of coronaviruses.
 
−
- The invention aims to treat and prevent respiratory virus-related medical conditions.
 
−
- The modulation of dysregulated immune responses is also targeted by the proposed treatment approach.
 
−
 
 
−
'''Abstract'''
 
−
Use of GABA-receptor agonists, either alone or with one or more positive PAMs, anti-inflammatory compounds, and/or antiviral treatments, e.g., one that limits viral replication or impacts other viral functions, to ameliorate, treat, and/or prevent illness arising from infections, including bacterial, fungal, and/or viral infections, inpatients, including to: ameliorate infection-related medical conditions; ameliorate and/or prevent coronavirus-related medical conditions; inhibit viral replication; inhibit corona virus replication; ameliorate and/or treat coronavirus-induced medical conditions; ameliorate and/or prevent respiratory virus-related medical conditions; and ameliorate and/or modulate dysregulated immune responses.
 
−
 
 
−
===CONJOINT THERAPIES FOR TREATING VIRAL INFECTIONS ([[US Patent Application 18178266. CONJOINT THERAPIES FOR TREATING VIRAL INFECTIONS simplified abstract|18178266]])===
 
  
  
Line 72: Line 52:
  
  
−
'''Brief explanation'''
+
===ANTI-DPP6 CHIMERIC ANTIGEN RECEPTOR BEARING REGULATORY T CELLS ([[US Patent Application 18034037. ANTI-DPP6 CHIMERIC ANTIGEN RECEPTOR BEARING REGULATORY T CELLS simplified abstract (The Regents of the University of California)|18034037]])===
−
- The patent application is about methods of treating coronavirus diseases.
 
−
- The method involves administering a combination of a PLpro inhibitor and an Mpro inhibitor.
 
−
- The purpose of the method is to treat coronavirus diseases.
 
−
- The patent application also includes associated compositions related to the method.
 
−
 
 
−
'''Abstract'''
 
−
The present disclosure relates to methods of treating coronavirus diseases comprising conjointly administering a combination of a PLpro inhibitor and an Mpro inhibitor, and to associated compositions.
 
−
 
 
−
===ANTI-DPP6 CHIMERIC ANTIGEN RECEPTOR BEARING REGULATORY T CELLS ([[US Patent Application 18034037. ANTI-DPP6 CHIMERIC ANTIGEN RECEPTOR BEARING REGULATORY T CELLS simplified abstract|18034037]])===
 
  
  
Line 89: Line 60:
  
  
−
'''Brief explanation'''
+
===ATTENUATED CANCER CELLS AND METHODS RELATED THERETO ([[US Patent Application 18032932. ATTENUATED CANCER CELLS AND METHODS RELATED THERETO simplified abstract (The Regents of the University of California)|18032932]])===
−
- The patent application is about regulatory T cells (Tregs) that have been engineered to express a specific protein called dipeptidyl aminopeptidase-like protein 6 (DPP6)-reactive chimeric antigen receptor (CAR).
 
−
- These engineered Tregs can be used in immunotherapy treatments for autoimmune, inflammatory, and degenerative diseases.
 
−
- Specifically, the Tregs expressing the anti-DPP6 CAR can be used to treat or prevent autoimmune diseases affecting the pancreas or central nervous system.
 
−
- The innovation involves using genetically modified Tregs to target specific proteins involved in autoimmune diseases, potentially providing a more targeted and effective treatment option.
 
−
- The patent application suggests that this approach could be beneficial for patients with autoimmune diseases of the pancreas or central nervous system.
 
−
 
 
−
'''Abstract'''
 
−
The present disclosure relates generally to regulatory T cells (Tregs) engineered to express a dipeptidyl aminopeptidase-like protein 6 (DPP6)-reactive chimeric antigen receptor (CAR). The engineered Tregs are suitable for use in immunotherapy regimens for autoimmune, inflammatory and degenerative diseases. In particular, the anti-DPP6 CAR expressing Tregs are suitable for treating or preventing autoimmune diseases of the pancreas or central nervous system.
 
−
 
 
−
===ATTENUATED CANCER CELLS AND METHODS RELATED THERETO ([[US Patent Application 18032932. ATTENUATED CANCER CELLS AND METHODS RELATED THERETO simplified abstract|18032932]])===
 
  
  
Line 107: Line 68:
  
  
−
'''Brief explanation'''
+
===MICROFLUDIC LAB-ON-CHIP DEVICE, MATRIX, SMALL MOLECULES AND THREE-DIMENSIONAL SPHEROIDS FOR CELL REPROGRAMMING ([[US Patent Application 18315370. MICROFLUDIC LAB-ON-CHIP DEVICE, MATRIX, SMALL MOLECULES AND THREE-DIMENSIONAL SPHEROIDS FOR CELL REPROGRAMMING simplified abstract (The Regents of the University of California)|18315370]])===
−
The patent application is about methods and compositions involving cryo-shocked cells for therapeutic purposes, particularly as a vaccine for treating or preventing cancer. The application also discloses methods of preparing dead cryo-shocked cells and delivering drugs to target tissues in patients.
 
−
 
 
−
* Cryo-shocked cells are used as therapeutic agents, potentially as a vaccine.
 
−
* The patent application includes methods for preparing dead cryo-shocked cells.
 
−
* The cryo-shocked cells can be administered to treat or prevent cancer.
 
−
* The application also discloses methods for delivering drugs to specific tissues in patients.
 
−
 
 
−
'''Abstract'''
 
−
Provided herein are methods and compositions related to cryo-shocked cells useful as therapeutic agents. The cryo-shocked cells may be formulated as a vaccine. Disclosed are methods of preparing dead cryo-shocked cells. Disclosed are also methods of treating or preventing cancer, comprising administering the cryo-shocked cells. Further, methods for delivering a drug to a target tissue of a patient are disclosed.
 
−
 
 
−
===MICROFLUDIC LAB-ON-CHIP DEVICE, MATRIX, SMALL MOLECULES AND THREE-DIMENSIONAL SPHEROIDS FOR CELL REPROGRAMMING ([[US Patent Application 18315370. MICROFLUDIC LAB-ON-CHIP DEVICE, MATRIX, SMALL MOLECULES AND THREE-DIMENSIONAL SPHEROIDS FOR CELL REPROGRAMMING simplified abstract|18315370]])===
 
  
  
Line 126: Line 76:
  
  
−
'''Brief explanation'''
+
===APPARATUS AND METHODS FOR METHYL MERCURY DETECTION AND CAPTURE ([[US Patent Application 18311630. APPARATUS AND METHODS FOR METHYL MERCURY DETECTION AND CAPTURE simplified abstract (The Regents of the University of California)|18311630]])===
−
- The patent application is about an invention that improves cellular reprogramming and gene editing techniques in biology.
 
−
- The invention overcomes the challenges of low and variable efficiencies in these technologies.
 
−
- It provides optimized methods and systems for cellular engineering and gene editing.
 
−
- The invention includes microfluidic devices, chemical treatment, cell adhesion manipulation, and 3D spheroid culture.
 
−
- These techniques modulate epigenetic changes and significantly enhance cell reprogramming and gene editing.
 
−
- The changes in genome-wide chromatin accessibility caused by the invention can guide gene silencing, activation, insertion, and editing.
 
−
 
 
−
'''Abstract'''
 
−
Cellular reprogramming and gene editing represent major advancements in biology, and has wide applications in regenerative medicine, disease therapy and drug screening. However, low and variable efficiencies have created significant roadblocks to the full application of these technologies. The invention disclosed herein overcomes these roadblocks by providing optimized methods and systems that are useful in a variety of cellular engineering and gene editing methodologies, including for example methods designed to enhance the reprogramming of somatic cells into neural cells or pluripotent cells. The invention provides innovative microfluidic devices, chemical treatment, cell adhesion manipulation, and 3D spheroid culture to modulate epigenetic changes and significantly enhance cell reprogramming and gene editing; the genome-wide chromatin accessibility changes caused by cell nuclear deformation, 3D culture, decreased cell adhesions, and the reduction of intracellular tension can provide guidance for guided gene silencing, activation, insertion and/or editing.
 
−
 
 
−
===APPARATUS AND METHODS FOR METHYL MERCURY DETECTION AND CAPTURE ([[US Patent Application 18311630. APPARATUS AND METHODS FOR METHYL MERCURY DETECTION AND CAPTURE simplified abstract|18311630]])===
 
  
  
Line 145: Line 84:
  
  
−
'''Brief explanation'''
+
===TRANSCRIPTION ACTIVE COMPLEX TARGETING CANCER DRUG FROM VIRAL PROTEIN SEQUENCE ([[US Patent Application 18248291. TRANSCRIPTION ACTIVE COMPLEX TARGETING CANCER DRUG FROM VIRAL PROTEIN SEQUENCE simplified abstract (The Regents of the University of California)|18248291]])===
−
- The patent application describes devices, systems, and methods for detecting and capturing mercury and methyl-mercury from water sources.
 
−
- The devices and methods are based on a polymer platform that contains thiol or sulfide moieties and phenol moieties capped with an acid labile cap.
 
−
- When the thiol groups capture the mercury or methyl-mercury, a proton is released, which catalyzes the cleaving of the acid labile cap.
 
−
- This cleaving process also produces a proton, allowing for a cascade of deprotonation reactions that enhance the detection limit.
 
−
- The polymer in solution can be detected and quantified, providing a means for measuring the amount of mercury or methyl-mercury present.
 
−
- The thiol binding permanently removes the mercury or methyl-mercury from the solution.
 
−
- The polymer platform can be adapted to a portable handheld device, making it convenient for on-site detection and capture of mercury and methyl-mercury.
 
−
 
 
−
'''Abstract'''
 
−
Devices, systems and methods for the detection and capture of mercury and methyl-mercury from aqueous sources are provided. The devices and methods are based on a polymer platform with thiol or sulfide moieties and phenol moieties capped with an acid labile protected with an acid labile cap. Capture of the Hg or MeHg by the thiol groups releases a proton that will subsequently catalyze the cleaving of the cap that also produces a proton so that one capture event can result in a cascade of deprotonaton reactions enhancing the detection limit. The polymer in solution can be detected and quantified. The thiol binding will also permanently remove the Hg or MeHg from the solution. The platform can be adapted to a portable handheld device.
 
−
 
 
−
===TRANSCRIPTION ACTIVE COMPLEX TARGETING CANCER DRUG FROM VIRAL PROTEIN SEQUENCE ([[US Patent Application 18248291. TRANSCRIPTION ACTIVE COMPLEX TARGETING CANCER DRUG FROM VIRAL PROTEIN SEQUENCE simplified abstract|18248291]])===
 
  
  
Line 165: Line 92:
  
  
−
'''Brief explanation'''
+
===MULTIMERIC PROTEIN COMPLEXES AS ANTIBODY SUBSTITUTES FOR NEUTRALIZATION OF VIRAL PATHOGENS IN PROPHYLACTIC AND THERAPEUTIC APPLICATIONS ([[US Patent Application 18028345. MULTIMERIC PROTEIN COMPLEXES AS ANTIBODY SUBSTITUTES FOR NEUTRALIZATION OF VIRAL PATHOGENS IN PROPHYLACTIC AND THERAPEUTIC APPLICATIONS simplified abstract (The Regents of the University of California)|18028345]])===
−
- The patent application describes a new invention that involves compositions and methods for treating diseases characterized by excessive cell proliferation, inflammatory conditions, or autoimmune diseases.
 
−
- The invention focuses on inhibiting the activity of a protein called MYC in cells, particularly in MYC-dependent cancer cells.
 
−
- The purpose of inhibiting MYC activity is to effectively treat the mentioned diseases.
 
−
- The invention provides a novel approach to target MYC activity, which may lead to more effective treatments for diseases involving excessive cell proliferation, inflammation, or autoimmunity.
 
−
 
 
−
'''Abstract'''
 
−
The present invention provides compositions and methods for treating a disease involving inappropriate or excessive cell proliferation or for treating an inflammatory condition or an autoimmune disease by inhibiting MYC activity in cells such as MYC-dependent cancer cells.
 
−
 
 
−
===MULTIMERIC PROTEIN COMPLEXES AS ANTIBODY SUBSTITUTES FOR NEUTRALIZATION OF VIRAL PATHOGENS IN PROPHYLACTIC AND THERAPEUTIC APPLICATIONS ([[US Patent Application 18028345. MULTIMERIC PROTEIN COMPLEXES AS ANTIBODY SUBSTITUTES FOR NEUTRALIZATION OF VIRAL PATHOGENS IN PROPHYLACTIC AND THERAPEUTIC APPLICATIONS simplified abstract|18028345]])===
 
  
  
Line 182: Line 100:
  
  
−
'''Brief explanation'''
+
===ANTI-CD46 ANTIBODIES AND METHODS OF USE ([[US Patent Application 17815514. ANTI-CD46 ANTIBODIES AND METHODS OF USE simplified abstract (The Regents of the University of California)|17815514]])===
−
The patent describes an engineered protein complex that can be used as a substitute for antibodies in treating viral infections, specifically COVID-19.
 
−
 
 
−
* The protein complex is made up of human proteins and has a specific symmetry.
 
−
* Each element of the protein complex contains a modified version of a human multimeric protein fused to a module containing multiple modified human beta solenoid proteins.
 
−
* The modified protein complex is also fused to a pathogen binding domain derived from humans.
 
−
* The patent also includes a separate antibody substitute composed of multiple pathogen binding domain complexes.
 
−
* The invention can be used in both preventive and therapeutic treatments for viral infections, particularly for neutralizing the SARS-CoV-2 virus.
 
−
 
 
−
'''Abstract'''
 
−
The present patent consists of an engineered multimeric protein complex as antibody substitute composed of human proteins, with an m-fold symmetry, with each m-fold element containing a modified monomeric protein derived from a symmetric human multimeric protein complex fused to a module containing n fused, modified human beta solenoid proteins (mBSP), and that fused to a human derived pathogen binding domain (PBD), as well as a separate antibody substitute composed of P human PBD complexes. The invention may find application in prophylactic and therapeutic treatments for viral infections, especially for COVID19 by neutralizing the SARS-CoV-2 virus.
 
−
 
 
−
===ANTI-CD46 ANTIBODIES AND METHODS OF USE ([[US Patent Application 17815514. ANTI-CD46 ANTIBODIES AND METHODS OF USE simplified abstract|17815514]])===
 
  
  
Line 202: Line 108:
  
  
−
'''Brief explanation'''
+
===MAGNETICALLY TUNABLE PLASMON COUPLING OF NANOSHELLS ENABLED BY SPACE-FREE CONFINED GROWTH ([[US Patent Application 18247960. MAGNETICALLY TUNABLE PLASMON COUPLING OF NANOSHELLS ENABLED BY SPACE-FREE CONFINED GROWTH simplified abstract (The Regents of the University of California)|18247960]])===
−
- The patent application describes methods for treating a subject with a specific type of cancer that has a modification at biomarker 1q21.
 
−
- The treatment involves administering an anti-CD46 antibody to the subject.
 
−
- The anti-CD46 antibody is given in a therapeutically effective amount.
 
−
- The purpose of the treatment is to target and treat the cancer characterized by the biomarker modification at 1q21.
 
−
 
 
−
'''Abstract'''
 
−
Disclosed herein are methods of treating a subject having a cancer characterized by a modification at biomarker 1q21, which comprises administering to the subject a therapeutically effective amount of an anti-CD46 antibody.
 
−
 
 
−
===MAGNETICALLY TUNABLE PLASMON COUPLING OF NANOSHELLS ENABLED BY SPACE-FREE CONFINED GROWTH ([[US Patent Application 18247960. MAGNETICALLY TUNABLE PLASMON COUPLING OF NANOSHELLS ENABLED BY SPACE-FREE CONFINED GROWTH simplified abstract|18247960]])===
 
  
  
Line 219: Line 116:
  
  
−
'''Brief explanation'''
+
===BIOMARKERS FOR BIPOLAR DISORDER AND SCHIZOPHRENIA ([[US Patent Application 18333231. BIOMARKERS FOR BIPOLAR DISORDER AND SCHIZOPHRENIA simplified abstract (The Regents of the University of California)|18333231]])===
−
The patent application describes a method for creating magnetic/plasmonic hybrid structures.
 
−
 
 
−
* Synthesizing colloidal magnetic nanoparticles
 
−
* Modifying the magnetic nanoparticles with a polymeric ligand in a solution
 
−
* Binding metal seed nanoparticles to the surface of the magnetic nanoparticles
 
−
* Performing a seed-mediated growth on the metal seed nanoparticles by reducing a metal salt in solution
 
−
* Resulting in the formation of magnetic/plasmonic hybrid structures
 
−
 
 
−
'''Abstract'''
 
−
A method of forming magnetic/plasmonic hybrid structures is disclosed. The method includes synthesizing colloidal magnetic nanoparticles; modifying the magnetic nanoparticles in a solution of a polymeric ligand; binding metal seed nanoparticles to the surface of the magnetic nanoparticles; and performing a seed-mediated growth on the metal seed nanoparticles by reducing a metal salt in solution to form the magnetic/plasmonic hybrid structures.
 
−
 
 
−
===BIOMARKERS FOR BIPOLAR DISORDER AND SCHIZOPHRENIA ([[US Patent Application 18333231. BIOMARKERS FOR BIPOLAR DISORDER AND SCHIZOPHRENIA simplified abstract|18333231]])===
 
  
  
Line 239: Line 124:
  
  
−
'''Brief explanation'''
+
===PLATINUM OXIDE NANOPARTICLES FOR ELECTROCHEMICAL HYDROGEN EVOLUTION AND METHODS FOR MAKING AND USING THE SAME ([[US Patent Application 18449110. PLATINUM OXIDE NANOPARTICLES FOR ELECTROCHEMICAL HYDROGEN EVOLUTION AND METHODS FOR MAKING AND USING THE SAME simplified abstract (The Regents of the University of California)|18449110]])===
−
- The patent application describes a new invention related to the diagnosis and differentiation of bipolar disorder and schizophrenia.
 
−
- The invention involves the use of specific combinations of biomarkers, which are proteins and RNA, to identify and distinguish between these two mental disorders.
 
−
- The methods described in the patent application can be used to differentiate, diagnose, and treat bipolar disorder and schizophrenia.
 
−
- The invention relies on examining relevant proteins and RNA in a patient sample to determine the presence of bipolar disorder or schizophrenia.
 
−
- The use of these biomarkers can provide more accurate and reliable diagnoses, leading to better treatment options for patients.
 
−
 
 
−
'''Abstract'''
 
−
The present invention provides combinations of biomarkers that can be used in the diagnosis and differentiation of bipolar disorder and schizophrenia. The present invention therefore provides methods of differentiating, diagnosing and treating bipolar disorder and schizophrenia, by examining relevant proteins and RNA in a patient sample.
 
−
 
 
−
===PLATINUM OXIDE NANOPARTICLES FOR ELECTROCHEMICAL HYDROGEN EVOLUTION AND METHODS FOR MAKING AND USING THE SAME ([[US Patent Application 18449110. PLATINUM OXIDE NANOPARTICLES FOR ELECTROCHEMICAL HYDROGEN EVOLUTION AND METHODS FOR MAKING AND USING THE SAME simplified abstract|18449110]])===
 
  
  
Line 257: Line 132:
  
  
−
'''Brief explanation'''
+
===ADAPTIVE ANY-FUEL CAMLESS RECIPROCATING ENGINE ([[US Patent Application 18301825. ADAPTIVE ANY-FUEL CAMLESS RECIPROCATING ENGINE simplified abstract (The Regents of the University of California)|18301825]])===
−
The patent application describes a catalyst composition that consists of two main components: graphitic carbon nitride and platinum oxide nanoparticles. The platinum oxide nanoparticles are arranged on the graphitic carbon nitride.
 
−
 
 
−
* The catalyst composition includes graphitic carbon nitride and platinum oxide nanoparticles.
 
−
* The platinum oxide nanoparticles are placed on the graphitic carbon nitride.
 
−
* The composition is designed to be used as a catalyst in various applications.
 
−
* The graphitic carbon nitride provides a stable and durable support for the platinum oxide nanoparticles.
 
−
* The platinum oxide nanoparticles enhance the catalytic activity of the composition.
 
−
* The composition can be used in various industries, such as fuel cells, chemical synthesis, and environmental remediation.
 
−
* The arrangement of the platinum oxide nanoparticles on the graphitic carbon nitride allows for efficient catalytic reactions.
 
−
* The composition offers improved performance and efficiency compared to existing catalyst compositions.
 
−
* The patent application aims to protect the unique combination of graphitic carbon nitride and platinum oxide nanoparticles as a catalyst composition.
 
−
 
 
−
'''Abstract'''
 
−
The catalyst composition includes graphitic carbon nitride and a plurality of platinum oxide nanoparticles disposed on the graphitic carbon nitride.
 
−
 
 
−
===ADAPTIVE ANY-FUEL CAMLESS RECIPROCATING ENGINE ([[US Patent Application 18301825. ADAPTIVE ANY-FUEL CAMLESS RECIPROCATING ENGINE simplified abstract|18301825]])===
 
  
  
Line 281: Line 140:
  
  
−
'''Brief explanation'''
+
===NONIMAGING ASYMMETRIC SHADELESS COLLECTOR ([[US Patent Application 18030729. NONIMAGING ASYMMETRIC SHADELESS COLLECTOR simplified abstract (The Regents of the University of California)|18030729]])===
−
The patent application describes an adaptive reciprocating engine that can use any type of fuel and adjust its operation based on sensor feedback.
 
−
* The engine incorporates high-speed optical sensors that collect gas property data using spectroscopic techniques.
 
−
* The collected data is used in real-time control loops to adaptively manage electronic actuation schemes.
 
−
* The engine can adjust its operation based on the type of fuel being used and the engine load.
 
−
* The adaptive control allows for optimized performance and efficiency across a range of operating conditions.
 
−
* The use of optical sensors and real-time control loops improves the accuracy and responsiveness of the engine's control system.
 
−
 
 
−
'''Abstract'''
 
−
An adaptive, any-fuel reciprocating engine using sensor feedback integration of high-speed optical sensors with real-time control loops to adaptively manage the electronic actuation schemes over a range of engine loads and fuels. The engine uses one or more optical sensors to collect specific types of gas property data via a spectroscopic technique to adaptively control various components within the engine.
 
−
 
 
−
===NONIMAGING ASYMMETRIC SHADELESS COLLECTOR ([[US Patent Application 18030729. NONIMAGING ASYMMETRIC SHADELESS COLLECTOR simplified abstract|18030729]])===
 
  
  
Line 300: Line 148:
  
  
−
'''Brief explanation'''
+
===IMAGE-BASED CELL SORTING SYSTEMS AND METHODS ([[US Patent Application 18295244. IMAGE-BASED CELL SORTING SYSTEMS AND METHODS simplified abstract (The Regents of the University of California)|18295244]])===
−
The patent application describes a solar collector that uses a wide-angle, nonimaging asymmetric optical reflector to collect solar energy. The collector includes a transparent tube that is evacuated or partially vacuumed, and at least two pipes with fluid flowing through them. The pipes are arranged in a flow-through configuration. The collector has a solar acceptance angle of about 40 degrees, allowing for passive solar tracking. The solar energy collected is transferred to the fluid in the form of heat. The fluid exiting the collector has a temperature range of 100°C to 250°C, and this thermal energy can be used to generate high-quality steam for solar industrial process heat applications.
 
−
 
 
−
* Solar collector uses a wide-angle, nonimaging asymmetric optical reflector
 
−
* Includes a transparent tube evacuated to a vacuum or partial vacuum
 
−
* At least two pipes with fluid flowing through them in a flow-through configuration
 
−
* Solar acceptance angle of about 40 degrees allows for passive solar tracking
 
−
* Solar energy collected is transferred to the fluid as heat
 
−
* Fluid exiting the collector has a temperature range of 100°C to 250°C
 
−
* Thermal energy of the fluid can be used to generate high-quality steam
 
−
* Designed for solar industrial process heat applications
 
−
 
 
−
'''Abstract'''
 
−
A solar collector comprising a wide-angle, nonimaging asymmetric optical reflector comprising a reflective film, an absorber assembly positioned within the optical reflector having a transparent tube evacuated to a vacuum or partial vacuum and at least two pipes with fluid flowing through the pipes, the pipes arranged in a flow-through configuration, wherein the solar acceptance angle of the collector is about 40 degrees, allowing for passive (stationary) solar tracking, and where the solar energy collected is transferred to the fluid in the form of heat. The fluid exiting the solar collector is in the range of 100° C. to 250° C., and the thermal energy of the fluid may be used to generate high-quality steam for solar industrial process heat applications.
 
−
 
 
−
===IMAGE-BASED CELL SORTING SYSTEMS AND METHODS ([[US Patent Application 18295244. IMAGE-BASED CELL SORTING SYSTEMS AND METHODS simplified abstract|18295244]])===
 
  
  
Line 323: Line 156:
  
  
−
'''Brief explanation'''
+
===BIOMIMETIC LEAF WETNESS SENSOR AND METHOD OF MANUFACTURE OF THE SAME ([[US Patent Application 18201886. BIOMIMETIC LEAF WETNESS SENSOR AND METHOD OF MANUFACTURE OF THE SAME simplified abstract (The Regents of the University of California)|18201886]])===
−
- The patent application is about systems, devices, and methods for imaging and sorting particles in a flow system, specifically cells in a flow cytometer.
 
−
- The system includes a device that allows particles to flow through a channel.
 
−
- An imaging system captures image data of the particles as they flow through the channel.
 
−
- A processing unit analyzes the image data to determine a property associated with each particle.
 
−
- Based on sorting criteria related to particle properties, the processing unit generates a control command for sorting the particles.
 
−
- An actuator is used to direct each particle into one of several output paths in real-time.
 
−
- The innovation allows for real-time imaging and sorting of particles, particularly cells, in a flow system.
 
−
- This technology can be used in flow cytometry applications for various purposes, such as cell analysis and sorting based on specific properties.
 
−
 
 
−
'''Abstract'''
 
−
Disclosed are systems, devices and methods for imaging and image-based sorting of particles in a flow system, including cells in a flow cytometer. In some aspects, a system includes a particle flow device to flow particles through a channel, an imaging system to obtain image data of a particle during flow through the channel, a processing unit to determine a property associated with the particle and to produce a control command for sorting the particle based on sorting criteria associated with particle properties, and an actuator to direct the particle into one of a plurality of output paths of the particle flow device in real-time.
 
−
 
 
−
===BIOMIMETIC LEAF WETNESS SENSOR AND METHOD OF MANUFACTURE OF THE SAME ([[US Patent Application 18201886. BIOMIMETIC LEAF WETNESS SENSOR AND METHOD OF MANUFACTURE OF THE SAME simplified abstract|18201886]])===
 
  
  
Line 344: Line 164:
  
  
−
'''Brief explanation'''
+
===Tandem Activity-Based Sensing and Labeling Strategy for Reactive Oxygen Species Imaging ([[US Patent Application 18363714. Tandem Activity-Based Sensing and Labeling Strategy for Reactive Oxygen Species Imaging simplified abstract (The Regents of the University of California)|18363714]])===
−
The abstract describes a biomimetic leaf wetness sensor that uses a capacitive sensor and a non-conductive polymer layer with a replica molded surface resembling a plant leaf.
 
−
 
 
−
* The sensor is designed to detect the wetness of leaves, similar to how a real leaf would get wet in nature.
 
−
* It includes a capacitive sensor, which measures changes in electrical capacitance to determine the presence of moisture.
 
−
* The sensor is covered with a non-conductive polymer layer that has a surface pattern replicating the texture and structure of a plant leaf.
 
−
* This replica molded surface helps to mimic the interaction between a real leaf and moisture, enhancing the accuracy of the sensor's wetness detection.
 
−
* The biomimetic design of the sensor allows for more realistic and reliable measurements of leaf wetness, which can be useful in various applications such as agriculture, plant research, and environmental monitoring.
 
−
 
 
−
'''Abstract'''
 
−
A biomimetic leaf wetness sensor includes a capacitive sensor and a non-conductive polymer layer disposed over the capacitive sensor. The layer includes a replica molded surface corresponding to a plant leaf.
 
−
 
 
−
===Tandem Activity-Based Sensing and Labeling Strategy for Reactive Oxygen Species Imaging ([[US Patent Application 18363714. Tandem Activity-Based Sensing and Labeling Strategy for Reactive Oxygen Species Imaging simplified abstract|18363714]])===
 
  
  
Line 364: Line 172:
  
  
−
'''Brief explanation'''
+
===GPCR SCREENING METHOD TO IDENTIFY NON-HALLUCINOGENIC COMPOUNDS ([[US Patent Application 18248934. GPCR SCREENING METHOD TO IDENTIFY NON-HALLUCINOGENIC COMPOUNDS simplified abstract (The Regents of the University of California)|18248934]])===
−
The patent application describes a method for detecting and labeling reactive oxygen species (ROS) using selective probes.
 
−
* The method allows for simultaneous sensing and labeling of ROS such as hydrogen peroxide, peroxynitrite, and organic peroxides.
 
−
* The probes used in the method are selective, meaning they specifically target and react with ROS.
 
−
* This tandem activity-based sensing and labeling approach provides a simplified and efficient way to detect and label ROS.
 
−
* The method has potential applications in various fields, including biomedical research and diagnostics.
 
−
* The innovation described in the patent application could lead to improved understanding and detection of ROS-related diseases and conditions.
 
−
 
 
−
'''Abstract'''
 
−
Selective probes provide tandem activity-based sensing and labeling of reactive oxygen species (ROS), such as hydrogen peroxide, peroxynitrite, and organic peroxides.
 
−
 
 
−
===GPCR SCREENING METHOD TO IDENTIFY NON-HALLUCINOGENIC COMPOUNDS ([[US Patent Application 18248934. GPCR SCREENING METHOD TO IDENTIFY NON-HALLUCINOGENIC COMPOUNDS simplified abstract|18248934]])===
 
  
  
Line 383: Line 180:
  
  
−
'''Brief explanation'''
+
===QUANTUM WRAPPER NETWORKING ([[US Patent Application 18248931. QUANTUM WRAPPER NETWORKING simplified abstract (The Regents of the University of California)|18248931]])===
−
The abstract of the patent application describes the invention of new fluorescent biosensors that can be used in various methods related to detecting and measuring the effects of hallucinogenic and antidepressant compounds. The abstract also mentions the availability of suitable kits for these purposes.
 
−
 
 
−
* New fluorescent biosensors have been developed for detecting ligand-induced hallucinogenic conformational changes in G Protein-Coupled Receptors (GPCRs).
 
−
* The biosensors can also be used to detect hallucinogenic compounds and non-hallucinogenic antidepressant compounds.
 
−
* The invention provides a method for measuring the hallucinogenic potential of a compound, as well as the antipsychotic potential of a compound.
 
−
* Suitable kits are available for performing these detection and measurement methods.
 
−
 
 
−
'''Abstract'''
 
−
New fluorescent biosensors are provided for use in methods of detecting a ligand-induced hallucinogenic conformational change of a G Protein-Coupled Receptor (GPCR), detecting a hallucinogenic compound, detecting a non-hallucinogenic antidepressant compound, measuring the hallucinogenic potential of a compound, measuring the antipsychotic potential of a compound, and suitable kits thereof.
 
−
 
 
−
===QUANTUM WRAPPER NETWORKING ([[US Patent Application 18248931. QUANTUM WRAPPER NETWORKING simplified abstract|18248931]])===
 
  
  
Line 400: Line 186:
  
 
Sung-Joo Ben Yoo
 
Sung-Joo Ben Yoo
−
 
−
 
−
'''Brief explanation'''
 
−
The patent application describes a system and method for transmitting quantum datagrams over a network.
 
−
* Quantum datagrams consist of a wrapper and a quantum data payload.
 
−
* The wrapper contains classical non-quantum optical bits, while the quantum data payload contains quantum bits (qubits).
 
−
* The system separates the wrapper from the quantum data payload to process the classical bits without disturbing the qubits.
 
−
* Based on the processed wrapper, the system makes a forwarding decision for the quantum datagram.
 
−
* This innovation enables the transportation of quantum datagrams over a network while preserving the integrity of the quantum data payload.
 
−
 
−
'''Abstract'''
 
−
One embodiment provides a system and method for transporting quantum datagrams over a network. During operation, a quantum datagram is obtained at a network node. The quantum datagram can include a wrapper and an optical quantum data payload, with the wrapper comprising classical non-quantum optical bits and the quantum data payload comprising quantum bits (qubits). The system separates the wrapper from the quantum data payload such that the classical bits included in the wrapper are processed while the qubits included in the quantum data payload remain undisturbed, and makes a forwarding decision for the quantum datagram based on the processed wrapper.
 

Latest revision as of 06:38, 7 December 2023

Summary of the patent applications from The Regents of the University of California on November 30th, 2023

The Regents of the University of California have recently filed several patents for various innovative technologies. These patents cover a range of fields, including quantum communication, biosensors, reactive oxygen species detection, leaf wetness sensing, particle imaging and sorting, solar energy collection, adaptive reciprocating engines, catalyst compositions, and mental disorder diagnosis.

In the field of quantum communication, the organization has developed a system and method for transmitting quantum datagrams over a network. This technology separates the classical non-quantum optical bits from the quantum data payload, allowing for the transportation of quantum datagrams while preserving the integrity of the quantum data payload.

The organization has also invented fluorescent biosensors for detecting and measuring the effects of hallucinogenic and antidepressant compounds. These biosensors can detect ligand-induced hallucinogenic conformational changes in G Protein-Coupled Receptors (GPCRs) and can be used to measure the hallucinogenic and antipsychotic potential of compounds.

Another patent application describes a method for detecting and labeling reactive oxygen species (ROS) using selective probes. This approach allows for simultaneous sensing and labeling of ROS, providing a simplified and efficient way to detect and label these species, which can be useful in biomedical research and diagnostics.

The organization has also developed a biomimetic leaf wetness sensor that accurately detects the wetness of leaves by mimicking the interaction between a real leaf and moisture. This sensor can find applications in agriculture, plant research, and environmental monitoring.

In the field of particle imaging and sorting, the organization has created a system for real-time imaging and sorting of particles, particularly cells, in a flow system. This technology can be used in flow cytometry applications for cell analysis and sorting based on specific properties.

The organization has also filed a patent for a solar collector that uses a wide-angle, nonimaging asymmetric optical reflector to collect solar energy. This collector can generate high-quality steam for solar industrial process heat applications.

In the field of engines, the organization has developed an adaptive reciprocating engine that can adjust its operation based on sensor feedback, allowing for optimized performance and efficiency across a range of operating conditions.

A catalyst composition consisting of graphitic carbon nitride and platinum oxide nanoparticles has also been patented. This composition offers improved performance and efficiency compared to existing catalyst compositions and can be used in fuel cells, chemical synthesis, and environmental remediation.

Lastly, the organization has invented a method for diagnosing and differentiating bipolar disorder and schizophrenia using specific combinations of biomarkers. This method provides more accurate and reliable diagnoses, leading to better treatment options for patients.

Notable applications of these technologies include quantum communication networks, detection and measurement of hallucinogenic and antidepressant compounds, improved understanding and detection of ROS-related diseases, realistic measurement of leaf wetness, advanced particle imaging and sorting in flow cytometry, efficient solar energy collection for industrial processes, optimized reciprocating engines, enhanced catalytic reactions, and improved diagnosis and treatment of bipolar disorder and schizophrenia.



Contents

Patent applications for The Regents of the University of California on November 30th, 2023

METHODS FOR NON-INVASIVE, LABEL-FREE IMAGING OF CELLULAR IMMUNE RESPONSE IN HUMAN SKIN USING A NONLINEAR OPTICAL MICROSCOPY IMAGING SYSTEM (18202874)

Main Inventor

Mihaela Balu


COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS (18028311)

Main Inventor

Daniel L. KAUFMAN


CONJOINT THERAPIES FOR TREATING VIRAL INFECTIONS (18178266)

Main Inventor

Varghese John


ANTI-DPP6 CHIMERIC ANTIGEN RECEPTOR BEARING REGULATORY T CELLS (18034037)

Main Inventor

Qizhi TANG


ATTENUATED CANCER CELLS AND METHODS RELATED THERETO (18032932)

Main Inventor

Zhen Gu


MICROFLUDIC LAB-ON-CHIP DEVICE, MATRIX, SMALL MOLECULES AND THREE-DIMENSIONAL SPHEROIDS FOR CELL REPROGRAMMING (18315370)

Main Inventor

Song Li


APPARATUS AND METHODS FOR METHYL MERCURY DETECTION AND CAPTURE (18311630)

Main Inventor

Jennifer Lu


TRANSCRIPTION ACTIVE COMPLEX TARGETING CANCER DRUG FROM VIRAL PROTEIN SEQUENCE (18248291)

Main Inventor

Yoshihiro Izumiya


MULTIMERIC PROTEIN COMPLEXES AS ANTIBODY SUBSTITUTES FOR NEUTRALIZATION OF VIRAL PATHOGENS IN PROPHYLACTIC AND THERAPEUTIC APPLICATIONS (18028345)

Main Inventor

Daniel L. COX


ANTI-CD46 ANTIBODIES AND METHODS OF USE (17815514)

Main Inventor

Bin Liu


MAGNETICALLY TUNABLE PLASMON COUPLING OF NANOSHELLS ENABLED BY SPACE-FREE CONFINED GROWTH (18247960)

Main Inventor

Yadong Yin


BIOMARKERS FOR BIPOLAR DISORDER AND SCHIZOPHRENIA (18333231)

Main Inventor

Terry W. Osborn


PLATINUM OXIDE NANOPARTICLES FOR ELECTROCHEMICAL HYDROGEN EVOLUTION AND METHODS FOR MAKING AND USING THE SAME (18449110)

Main Inventor

Shaowei Chen


ADAPTIVE ANY-FUEL CAMLESS RECIPROCATING ENGINE (18301825)

Main Inventor

Raymond Mitchell Spearrin


NONIMAGING ASYMMETRIC SHADELESS COLLECTOR (18030729)

Main Inventor

Bennett WIDYOLAR


IMAGE-BASED CELL SORTING SYSTEMS AND METHODS (18295244)

Main Inventor

Yu-Hwa Lo


BIOMIMETIC LEAF WETNESS SENSOR AND METHOD OF MANUFACTURE OF THE SAME (18201886)

Main Inventor

Marco Rolandi


Tandem Activity-Based Sensing and Labeling Strategy for Reactive Oxygen Species Imaging (18363714)

Main Inventor

Christopher J. Chang


GPCR SCREENING METHOD TO IDENTIFY NON-HALLUCINOGENIC COMPOUNDS (18248934)

Main Inventor

Chunyang DONG


QUANTUM WRAPPER NETWORKING (18248931)

Main Inventor

Sung-Joo Ben Yoo

Retrieved from "http://wikipatents.org/index.php?title=The_Regents_of_the_University_of_California_patent_applications_published_on_November_30th,_2023&oldid=15640"